Computational models represent a highly suitable framework, not only for testing biological hypotheses and generating new ones but also for optimising experimental strategies. As one surveys the literature devoted to cancer modelling, it is obvious that immense progress has been made in applying simulation techniques to the study of cancer biology, although the full impact has yet to be realised. For example, there are excellent models to describe cancer incidence rates or factors for early disease detection, but these predictions are unable to explain the functional and molecular changes that are associated with tumour progression. In addition, it is crucial that interactions between mechanical effects, and intracellular and intercellular signalling are incorporated in order to understand cancer growth, its interaction with the extracellular microenvironment and invasion of secondary sites. There is a compelling need to tailor new, physiologically relevant in silico models that are specialised for particular types of cancer, such as ovarian cancer owing to its unique route of metastasis, which are capable of investigating anti-cancer therapies, and generating both qualitative and quantitative predictions. This Commentary will focus on how computational simulation approaches can advance our understanding of ovarian cancer progression and treatment, in particular, with the help of multicellular cancer spheroids, and thus, can inform biological hypothesis and experimental design.
Introduction
Ovarian cancer remains an important health problem owing to its high lethality; it has the highest mortality rate of all gynaecological tumours and is the fifth leading cause of female cancer deaths. This disease is referred to as a silent killer because of its asymptomatic early stages (Le Page et al., 2004) . Most patients are diagnosed at an advanced stage of this disease, with metastatic outgrowth beyond the ovary and poor survival prognosis. Initially, patients respond to cytoreductive surgery and a platinum-and taxane-based chemotherapy, but owing to the occurrence of chemoresistance, there is only a cure rate of 30% (Bast et al., 2009; Lengyel, 2010) . Designing improved therapies to achieve a long-term cure has remained a challenge because little is known about the underlying mechanisms promoting ovarian cancer progression, its tumour-stroma microenvironment and how chemoresistance occurs (Agarwal and Kaye, 2003) .
A set of intricate cellular interactions characterise the biological nature of cancerous tissues, and the complex crosstalk of these processes spans multiple scales, for which mathematical simulation techniques can provide a systems-level understanding (Fig. 1) . The development of a virtual tool, which integrates the disciplines of engineering and cell biology to create a multiscale, patient-specific in silico representation of cancerous cells and tissues is arguably the ultimate goal of this interdisciplinary research area (Anderson and Quaranta, 2008; Deisboeck et al., 2011; Kam et al., 2012) . Such computational models are designed to improve our knowledge of the 'pathophysiological phenomena' of cancer, to screen chemoand radiotherapeutics, and in some cases to help us develop surgical strategies to arrest the growth of primary tumours and disease progression to secondary sites (Brown and Palmer, 2009; Kohandel et al., 2006; Montalenti et al., 1998; Panetta, 1997) . The majority of previous mathematical models have focused on breast and prostate cancer, as both cancer types have the highest incidence rates in females and males, respectively (Chakrabarti et al., 2012; Jain et al., 2011; Siegel et al., 2012) . However, there are a few studies that mathematically model ovarian cancer and address relevant aspects of tumour growth and angiogenesis, which indicates the efficacy of predictive techniques in hypothesis testing related to anti-cancer agents, such as cellcycle and non-cell-cycle-specific therapeutics (Brown and Palmer, 2009; Kohandel et al., 2006; Montalenti et al., 1998; Panetta, 1997) .
The purpose of this Commentary is to provide an overview of the pathogenesis of ovarian cancer, a review of experimental approaches used to investigate the growth of cancer spheroids and their microenvironment, and a consideration of mathematical techniques used to predict tumour growth, treatment and disease progression. We will also discuss simulation techniques used for breast and prostate cancer, and address areas that are in need of advancement for future research efforts, such as multiscale modelling approaches and patient-specific input parameters.
Pathogenesis of ovarian cancer
The aetiology of ovarian cancer is still incompletely understood. Several risk factors, such as age, family history and nulliparity have a role in the pathogenesis of this disease. Ovarian cancer is divided into three subgroups -epithelial, stromal and germ cell tumours -of which epithelial ovarian cancer (see Box 1) is the most common and lethal type (Bast et al., 2009; Cannistra, 2004; Shih and Davidson, 2009) . It has been postulated that ovarian carcinomas can develop from any of four different origins: the ovarian surface epithelium, the fallopian tube epithelium, cells lining subsurface inclusion cysts or the peritoneal cavity (Bast et al., 2009; Cannistra, 2004) . Direct evidence for the possible fallopian tube origin has been provided using a double knockout animal model with a reproductive tractspecific deletion in the microRNA processing enzyme Dicer and the tumour suppressor phosphatase and tensin homologue (Pten) . In this animal study, ovarian carcinomas arise from the stromal compartment of the fallopian tube rather than the epithelial layer and show molecular characteristics that are similar to those seen in patients .
Ovarian carcinomas have a unique route to metastasis through the intraperitoneal dissemination of cancer cells within the tumour (ascites) fluid. Cancer cells detach from the primary tumour, either as single cells or multicellular spheroids, by reorganising their cell-cell and/or cell-matrix adhesions, and exerting cancer-associated proteolytic functions. These cells then adhere to the mesothelial cell layer that covers the peritoneal organs and invade into the underlying extracellular matrix (ECM), where they grow secondary tumours. These events are clearly the crucial steps that lead to poor patient outcomes (Burleson et al., 2005; Dong et al., 2010; Moss et al., 2009; Sawada et al., 2008; Symowicz et al., 2007) . However, little is known with regards to the underlying mechanisms that facilitate metastasis and subsequently result in chemoresistance. Primary tumours, their metastatic lesions and tumour xenografts have similar gene expression patterns, which opens a therapeutic window to target both the source of the primary tumour and the metastatic lesion by developing novel anti-cancer agents (Lengyel, 2010; Moss et al., 2009; Zietarska et al., 2007) .
Macroscale
Discrete or continuum models to predict (ovarian cancer) tissue biology and biomechanics.
Microscale
Tissue-cell mechano-or chemo-environment, nutrient transport from stroma or microenvironment to cancer spheroids.
Nanoscale
Intracellular signalling events, intercellular mechanical interactions, cell phenotypical traits and molecular dynamics.
Macroscale
In vitro ovarian cancer models using 3D co-cultures reflecting tissue conditions.
Microscale
Quantification of macro-scaled co-cultures, confocal and electron microscopy, histology and immunocytochemistry.
Nanoscale
Quantitative analyses of gene and protein expression (RT-PCR, western blot analyses), cell cycle and growth or death indices. Fig. 1 . Integrated computational and experimental models of cancer from macroscale through to nanoscale. A set of intricate cellular interactions characterise the biological nature of cancerous tissues and the complex crosstalk of these processes spans multiple scales, for which mathematical simulation techniques can provide a systems-level understanding. Within each stream, mathematical predictions can be made by incorporating cancer-associated, cellular, biomechanical and biochemical processes that occur across spatial scales ranging from the macro-to micro-and nanoscales. The multiscale modelling framework depicted here represents a natural framework for testing biological hypotheses, generating new ones and optimising experimental design. The images (right column) illustrate the different cellular scales used to apply computational and experimental models: a schematic and confocal micrograph of 3D co-cultures represent the macroscale (cell actin filaments stained with rhodamine415-conjugated phalloidin, red), a scanning electron micrograph of the cancer cell network indicates the microscale, and a confocal micrograph of a cancer spheroid shows the nanoscale (cell actin filaments stained with rhodamine415-conjugated phalloidin, red; nuclei stained with 49,6-diamidino-2-phenylindole, blue; protein stain using respective primary and secondary Alexa488-conjugated antibodies, green).
Mathematical models Experimental models
These findings suggest that the spheroid population in the peritoneal fluid represents the main source for intra-abdominal outgrowth, and therefore, is a key target for anti-metastatic therapies.
Experimental modelling of multicellular cancer spheroids Multicellular cancer spheroids link the tumour to the development of microregions of heterogenous cells, micrometastasis and an abnormal microenvironment. Crucial differences in the cellular microenvironment occur over very small distances of 10 to 20 cell diameters. Proliferating cells are located in the outer three to five cell layers of a spheroid, and quiescent cells reside more centrally. Such avascular spheroids display density and metabolite gradients that hinder therapeutic agents from reaching their target (Sutherland, 1988) . Cancer spheroids with diameters between 200 and 500 mm develop gradients of oxygen, nutrients and catabolites, with a necrotic core that is typically observed at sizes .500 mm (Hirschhaeuser et al., 2010) . The relevance of spheroids in the progression of ovarian tumours has been reviewed elsewhere (Shield et al., 2009) . Interestingly, spheroids derived from peritoneal fluid of patients with the advanced stages of the disease (FIGO III-IV; see Box 1) range in number (from two to more than 20) and size (from 30 to 750 mm in diameter), suggesting that there is a high patient-topatient variability (Burleson et al., 2004a; Casey et al., 2001) .
The mechanism of formation of multicellular spheroids is still not completely understood. Primary cancer cells can either detach as single cells and then aggregate to form spheroids in order to survive within the peritoneal cavity, or detach as cell sheets that are assembled while free-floating in the peritoneal fluid. The shedding of these multicellular masses might be more successful for intraperitoneal dissemination and secretion of proteases, which is required for migration and invasion into abdominal lesions. It is also unknown whether primary cancer cells adhere and invade into the secondary site (e.g. omentum, peritoneum) as single cells or as spheroids, or whether they prepare these secondary sites for successful colonisation (Lengyel, 2010; Moss et al., 2009) . Spheroids are distributed through a passive mechanism as they are carried by the physiological force of the peritoneal fluid to the secondary sites, following the 'seed and soil' theory of non-random patterns of metastasis. Complex interactions between tumour cells and their surrounding host cells are crucial for tumorigenesis, whereby tumour cells (the 'seed') target specific organs (the 'soil'); hence, metastases only occur when the 'seed' (i.e. ovarian cancer cells) and 'soil' (i.e. mesothelium) are compatible (Fidler, 2003; Mathot and Stenninger, 2012; Paget, 1889; Ribatti et al., 2006) .
To experimentally model the growth of multicellular spheroids, three-dimensional (3D) cell culture approaches have been developed (Abbott, 2003; Lutolf and Hubbell, 2005; Yamada and Cukierman, 2007) . 3D cultures consist of cells that are aggregated in spheroids, which harbour an intermediate complexity and cellular heterogeneity between that of in vitro monolayers and in vivo tumours. The importance of 3D architecture and spheroid model systems has been extensively reviewed and clearly illustrates that cell-matrix interactions are better recreated by a complex aggregated cell population rather than a simple cell monolayer (Bissell and Radisky, 2001; Debnath and Brugge, 2005; Friedrich et al., 2007; Griffith and Swartz, 2006; Hutmacher et al., 2010; Pampaloni et al., 2007) . However, the term spheroid is inconsistently used throughout the literature, although its definition is crucial to the rationale of spheroid-based experimental and mathematical modelling. Spheroids comprise a defined 3D structure of uniform geometry and physiological, non-linear gradients that can be modulated, making them suitable for high-throughput, preclinical drug screening routines (Hirschhaeuser et al., 2010) .
Our group employs an interdisciplinary approach that aligns bioengineered 3D cell culture platforms with molecular and cell biology driven research to deliver a better understanding of cancer progression, more reliable diagnostics and improved treatment intervention Loessner et al., 2013; Loessner et al., 2010) . We applied this experimental 3D approach to monitor gene expression profiles by using high-throughput screening to analyse cancer-associated proteases (e.g. kallikreinrelated serine peptidases), the response to chemotherapeutics (e.g. taxane-based agents) and stromal parameters (e.g. the presence of mesothelial cells). We identified both known signalling pathways, such as Wnt-b-catenin and integrin-mediated cascades, and new pathways linked to tumorigenesis (D. Loessner, unpublished observations).
The mechanical properties of bioengineered microenvironments can be modified to study cellular behaviour; hence, they offer a
Box 1. Biology of ovarian cancer
There are four histological subtypes of epithelial ovarian cancer: serous, endometrioid, clear cell and mucinous ovarian adenocarcinoma. These are defined by their differentiation status, with the serous subtype being the most frequent and deadly. Each subtype is further grouped into: benign (cystadenoma), malignant (carcinoma) and borderline (lowmalignant-potential), on the basis of their clinical behaviour. Eschewing clinicopathological characteristics, two important subcategories -low-grade and high-grade malignanciespresent alterations in ovarian cancer-associated genes and pathways. Low-grade carcinomas are confined to the ovary with an indolent clinical course, whereas high-grade tumours are associated with an aggressive phenotype, occurrence of metastasis and poor clinical outcome (Bast et al., 2009; Cannistra, 2004; Shih and Davidson, 2009 ).
The staging system for ovarian cancer was defined by the International Federation of Gynaecology and Obstetrics (FIGO) according to the volume and extent of tumour spread. FIGO I-II comprises the early stage, where the tumour is limited to one or both ovaries (FIGO I) and other pelvic organs, such as uterus or fallopian tubes (FIGO II). FIGO III-IV is defined as late-stage or advanced disease, with involvement of the upper abdomen, omentum or lymph nodes (FIGO III) and distant metastasis to the liver or pleural space (FIGO IV) (Cannistra, 2004) . Due to the lack of specific symptoms in the early stages and effective screening strategies, the majority of patients are diagnosed with late stage disease (FIGO III-IV). The clinically established serum marker cancer antigen 125 (CA-125, also known as mucin 16) is elevated in ovarian cancer but often results in false positives, and its sensitivity is very low to detect early stage disease, therapeutic response and recurrence. The cancer-associated expression of kallikrein-related peptidases (KLK), in particular KLK5, and the human epididymis protein 4 (HE4, also known as WFDC2) are promising complementary biomarkers for ovarian carcinoma (Dorn et al., 2011; Hellströ m et al., 2003; Schummer et al., 2012; Yousef and Diamandis, 2009; Yousef et al., 2003). distinct advantage over monolayer cultures (Butcher et al., 2009 ). Loss of tissue homeostasis, reflected by an altered micro-rheology, matrix stiffening, cell-generated and compression forces, is a hallmark of disease. We were able to show that a uniform spheroid formation correlates with microenvironmental stiffness and is inversely associated with the mechanical properties of the microenvironment . Another group has shown that the invasive behaviour of ovarian cancer cells is inversely correlated with their stiffness, leading to cytoskeletal remodelling and altered cell adhesion, which is indicative of a progressive disease stage (Xu et al., 2012) . However, these mechanical properties were measured using individual cells, whereas the stiffness of ovarian cancer spheroids or patientderived cancer cells has not been determined yet. Our preliminary results suggest that spheroids and tumour tissue derived from spheroid-based xenografts are softer than ovarian tissue (D. Loessner, unpublished observations). Nevertheless, stiffness might be a useful indicator of the metastatic potential of this disease, although it is unknown whether or not cancer cells are mechanically pre-conditioning their metastatic sites.
Experimental modelling of multicellular cancer spheroids and their microenvironment
The main microenvironment for ovarian cancer cells is the mesothelium, covering all organs of the peritoneum. The mesothelium is a cell monolayer attached to a basement membrane, which is predominantly composed of collagen types I and IV, fibronectin and laminin. When disseminated spheroids adhere to this secondary site, integrin a2b1-collagen type IV, a5b1-fibronectin and a6b1-laminin interactions occur, which promote the adhesion of cancer cells to the mesothelium. At the same time, cancer-associated proteases degrade the basement membrane and allow invasion of the mesothelium (Burleson et al., 2004a; Casey et al., 2001; Kenny et al., 2008) . It has been shown that cancer cells do not directly adhere to mesothelial cells, but rather to the underlying matrix. This spheroid-mesothelium crosstalk occurs through integrin-and talin-dependent activation of myosin, and contractile forces that are produced by spreading cancer cells, thus mediating a displacement of mesothelial cells from beneath the spheroids (Iwanicki et al., 2011) .
Abnormal microenvironmental changes can stimulate cancerous growth; in fact, inflammation associated with wound healing mediates the development of epithelial tumours (Bissell and Radisky, 2001) . Tumours activate some of the normal woundhealing cascades, such as the formation of a fibrin clot and the release of growth factors (Dvorak, 1986) . Hence, our group uses a bioengineered microenvironment that mimics the fibrin clot to provide the cancer cell niche during progression of ovarian cancer. We developed an integrated 3D co-culture model of ovarian cancer and mesothelial cells, which reflects the tumour-stroma microenvironment of advanced-stage disease. Initial highthroughput gene expression analyses and signalling profiling show that spheroid growth is enhanced, and that genes regulating cell cycle and growth are upregulated in 3D co-cultures, highlighting the importance of tumour-stroma interactions in disease progression (D. Loessner, unpublished observations). Such spheroid-based co-culture models exhibit the cellular heterogeneity of tumour tissues, and have become increasingly useful 3D platforms (Hirschhaeuser et al., 2010; Iwanicki et al., 2011; Meli et al., 2012; Schwartz and Chen, 2013) to deliver the mechanobiological simulation parameters for computational models with the aim of elucidating the factors that promote tumour growth and treatment.
Continuum and discrete in silico techniques to analyse tumour growth and treatment Mathematical modelling in systems biology, from developmental to cancer cell biology, already dates back to the mid-20th century (Byrne, 2010; Tomlin and Axelrod, 2007) . Over the past decades, there has been substantial progress in experimental technologies to obtain quantitative data from cell cultures and tissues, which form the basis of the simulation parameters in a computational model (Oates et al., 2009; Tomlin and Axelrod, 2007) . Current advances in microscopic imaging techniques and molecular biology (Robinson et al., 2000) have provided a means by which the existing 'synthetic biology' (Endler et al., 2009) community can obtain detailed biological data to better inform model input parameters and validate predictions of biological interactions that occur from the cellular to the tissue level (Fig. 1) .
Continuum modelling techniques
Continuum methods (see Box 2) have been used to predict mechanisms of tumour initiation and growth (Chaplain, 1996; Greenspan, 1976; Marcu et al., 2002; Please et al., 1998) , and to elucidate the relationship between tumour morphology and spatial variations of microenvironmental parameters (Frieboes et al., 2006) . These in silico techniques can predict therapy outcomes (e.g. cell-cycle and non-cell-cycle-specific therapeutics, hormone therapy and radiotherapy), surgical efficacy and cancer cell kinetics, thus being able to propose the therapeutic intervention that yields the best possible patient outcome (Jain et al., 2011; Kohandel et al., 2006; Marcu et al., 2005; Montalenti et al., 1998; Panetta, 1997; Rockne et al., 2010) .
Brown and Palmer used a probabilistic model (see Box 2) to provide a novel simulation tool for the early detection of ovarian cancer to predict survival and diagnosis of unsuspected ovarian cancer, for which there is a lack of preclinical evidence for ovarian cancer (Brown and Palmer, 2009 ). On the basis of this model, a tumour needs more than four years to grow (FIGO I-II) and one year to progress (FIGO III-IV) before it becomes clinically apparent. Advanced-stage tumours (FIGO III-IV) start to metastasise when they reach a diameter of 3 cm (Brown and Palmer, 2009 ). To achieve a sensitivity of 50% in early detection (FIGO I-II), the size of the tumour would need to be ,1.3 cm, and to reduce the mortality rate by 50%, an early diagnostic screen needs to be able to detect a tumour of ,0.5 cm in size. Despite the challenge of estimating parameters, such as time and size of the tumour, these simulations are in agreement with clinical observations of the median diameter for advanced-stage ovarian tumours, demonstrating the efficacy of this mathematical approach.
Discrete modelling techniques
Continuum models do not provide resolution at the scale of individual cells, which is an important feature of discrete and hybrid models (see Box 2). Hybrid models represent cancer cells discretely, and their host tissue (ECM), matrix-degrading enzymes and nutrient concentrations (oxygen) as continuous variables. Although this in silico technique might be limiting because considerable computing power is required for large-scale simulations, its advantage lies in the ability to predict the complexity of intra-and intercellular interactions, and cell phenotypical traits that are guided by the local microenvironment (Fig. 2) .
Hybrid models have been used to investigate not only tumour growth (Drasdo and Hohme, 2005; Jiang et al., 2005; Macklin et al., 2010; Mansury et al., 2006; Stott et al., 1999) , but also tumour-induced angiogenesis (Anderson and Chaplain, 1998; Macklin et al., 2009; Perfahl et al., 2011; Shirinifard et al., 2009 ) and tumour morphology Anderson et al., 2006) . By their nature, these models incorporate spatial variables that are associated with the tumour architecture. The discrete representation of cells, which is inherent to hybrid methods, has allowed predictions of cell-cell and cell-matrix interactions, and tumour morphology, suggesting that a heterogeneous ECM leads to an invasive, asymmetric phenotype (Anderson et al., 2006) . Simulations of the mechanobiological impact on cell kinetics have indicated that tumour growth is 'biomechanically mediated' during the later phases of growth, and that biomechanical factors might alter cell cycle phases and balance nutrient gradients at the spheroid periphery (Drasdo and Höhme, 2005; Macklin et al., 2009; Mansury and Deisboeck, 2003) . Hybrid methods have also been used to infer potentially emerging behaviours, such as the crosstalk between cancer cell signalling, proliferation and invasion (Mansury and Deisboeck, 2003) .
Simulating patient-specific outcomes
Patient-specific predictions of tumour growth, progression and response to therapy are crucial because they are not generalised to population-derived, representative parameters, but instead are individualised to predict the outcome for a single person. Recently, advanced experimental techniques that are capable of providing sufficient detail to allow a patient-specific calibration of model parameters have become available. Both discrete and continuum approaches have been used to incorporate patientderived parameters and resulted in predictive potential of patientspecific tumour growth (Dionysiou et al., 2006; Macklin et al., 2012; Perfahl et al., 2011) and response to radiotherapy (Neal et al., 2013; Rockne et al., 2010; Stamatakos et al., 2010) . Patient-derived details that are used to individualise these models include 3D imaging of the tumour morphology, its histopathology and its genetic characteristics (Dionysiou et al., 2006; Neal et al., 2013; Rockne et al., 2010) .
Finite element analysis
Finite element analysis (FEA) is a numerical method to simulate the mechanical forces and internal stresses that act on physical structures. This technique involves the discretization of a complex solution domain (e.g. individual cells or multicellular spheroids) into smaller regions. A solution is calculated for equations that describe field variables in each of these subregions, and the cumulative solution for these subregions will provide a solution for the entire domain. This method has been applied to the mechanical interactions between cells (Brodland and Veldhuis, 2012a; Brodland and Veldhuis, 2012b; Erdemir et al., 2012; Viens and Brodland, 2007; Wong and Tang, 2011; Yang and Brodland, 2009 ) and the surrounding matrix (Koch et al., 2012) . For instance, a cell-based FEA predicted that intercellular mechanical forces of a particular type and magnitude are crucial for cancer cell invasion (Brodland and Veldhuis, 2012b) . In addition, a nanoscale FEA predicted that an increased intracellular strain energy is associated with enhanced traction forces and cell invasion (Koch et al., 2012) .
In summary, a set of intricate cellular interactions characterise the physiological context of tumour growth, and the complex crosstalk of these processes spans multiple scales. Gaining a systems-level understanding of these inter-relationships requires the definition and management of multiple parameters over multiple scales, which is often technically, if not economically, prohibitive to achieve experimentally. Biologically based simulations allow the simultaneous testing of multiple experimentally driven hypotheses over a wide range of parameters, which is also very difficult to achieve experimentally (Kam et al., 2012) . In this context, in silico modelling has the potential to improve our mechanistic
Box 2. Continuum, discrete and hybrid mathematical modelling approaches in cancer biology
There are recent augmentations of in silico techniques that have opened a new focus on cancer research, such as agent-based methods (ABM), which allow a more realistic simulation of cell movement in arbitrary directions in contrast to other discrete methods. Computational simulations of cancer cell behaviour typically utilise either continuum or discrete methods (Byrne and Drasdo, 2009 ) or a combination of both, known as a hybrid technique (Anderson, 2005; Deisboeck et al., 2011; Kam et al., 2012; Quaranta et al., 2005) .
Continuum modelling approaches consider the tumour and/or cellular microenvironments as a continuous medium, providing resolution at the scale of an individual cell or multicellular structures. These mathematical methods generally use partial differential equations that incorporate growth and kinetic interactions between species, and fluxes for active and passive transport. By their nature, these models are deterministic, and a key advantage is their success in simulating clinically sized tumours. In the context of continuum approaches to cancer simulation, probabilistic models incorporate statistical analysis techniques to describe a relationship between model variables on the basis of statistical relationships derived from historical data.
Discrete or cellular automaton modelling approaches permit individual cells (or agents) to be represented explicitly, allowing cell-cell interactions to be guided by a set of pre-defined rules and permitting cell state to be tracked in space and time. Such models are capable of representing cellular responses, such as intra-and intercellular interactions, signalling pathways, cell polarity and the influence of the tumour-stroma microenvironment on phenotypical traits. Cellular automaton models permit the spatial verification of these factors. Although there are several methods of cellular automaton modelling that have been developed to simulate physical, biological and scientific phenomena, in the context of cancer biology, the most common method is the ABM. A key feature of these models is their ability to provide lattice-free representations of cells, thereby allowing cells to migrate in arbitrary directions. The 'cellular potts' model has also been applied to the study of tumour growth and provides an added level of complexity by discretizing the actual cell, allowing cell volume and shape to be represented specifically.
Hybrid modelling approaches combine both the continuum and discrete approaches in order to incorporate the advantages of both methods. When applied to cancer biology, this technique generally incorporates continuum descriptions for the environmental and population scale variables, such as nutrient concentration, coupled with a discrete representation of the cells, which are then influenced by variations in the continuum variables.
understanding of tumour growth and treatment, to provide a means to generate biological hypotheses and to inform experimental design.
In silico modelling to predict disease progression The microenvironmental signature of ovarian cancer progression contains different regulatory components, such as pericellular adhesions, tumour (ascites) fluid and the peritoneum. The pericellular adhesive microenvironment is characterised by the phenotypic plasticity of the ovarian surface epithelium and the remodelling of integrins and cadherins during malignant transformation, which facilitate metastatic dissemination and a loss of cell polarity (see Box 3). Cancer cells within the peritoneal fluid lack integrin-matrix contacts, but maintain cadherin-mediated adhesions, and are exposed to diverse soluble factors, such as growth factors, proteases or bioactive fragments, which are secreted by both cancer and stromal cells, and influence cell survival and motility. Upon peritoneal anchorage, integrin-matrix adhesions are re-established, and integrin-mediated signalling and proteolytic functions potentiate metastatic outgrowth. However, our understanding of the molecular and spatio-temporal regulation of these processes is still incomplete. The design of experimental models that accurately reflect the progressive disease is scientifically challenging owing to the unique route of ovarian cancer metastasis, the formation of multicellular spheroids. These spheroids grow anchorage-independently and are resistant to chemotherapy, which is indicative of specific survival mechanisms Dong et al., 2010; Moss et al., 2009; Shield et al., 2009) .
Microscale simulations that are capable of capturing the biological, chemical and mechanical cues that control these signalling pathways might shed light on the effect of cell polarity components on cell function in malignant tissues. Simulations that address individual cancer cells have attempted to capture the inter-relationship between the cell cycle, cell-cell adhesions, the surface density of cell receptors and chemotactic responses to nutrient gradients Rejniak, 2005) , and have proposed roles for cadherin-mediated adhesions and related signalling pathways (Ramis-Conde and Drasdo, 2012) . However, compared with predictions of multicellular cancer growth, the use of in silico techniques to reproduce the complex cellular dynamics that govern the behaviour of the cancer cells in their microenvironment is still in its infancy. Nevertheless, with advances in computational techniques, more detailed simulations of these signalling cascades are being developed, which can be verified with sophisticated experimental methods. Simulations of the mechanical cues that regulate cellular processes have demonstrated the dynamic nature of the mechanical strength of focal adhesions, and that the cell can actively change these to alter its migration velocity (Wong and Tang, 2011) . However, there are still knowledge gaps with regards to how mechanical forces can influence intracellular processes (Gao et al., 2011; Kim et al., 2011 Fig. 2 . Illustration of a road map for multiscale alignment of experimental and mathematical modelling. Molecular processes that occur in the host and tumour tissue at different cellular and genetic scales can be assessed using analytical and computational modelling techniques. Their interrelationship is ensured through the combined validation and verification at each scale. The analysis of tumour tissues (marcoscale) involves immunohistochemistry and tissue microarrays. Cellular changes (microscale) can be determined using growth analysis, microscopy, quantitative imaging and morphological analyses. Genetic changes (nanoscale) can be quantified by microarray and pathway analyses. Diffusion equations simulate microenvironmental gradients (macro-and microscale) and intracellular micro-constituents through the cytosol (nanoscale) as a continuum. Growth models predict tissue and/or tumour growth within organs that are modified as a response to chemotherapeutics. Probabilistic techniques, such as the Taguchi, Monte Carlo or Kaplan Meir methods, describe the relationship between model variables on the basis of statistical relationships derived from experimental data at multiple scales. Finite element analysis (FEA) is a numerical method used to predict the tissue (macroscale), spheroid (microscale) mechanobiology and internal stresses (nanoscale) acting on physical structures. Cellular automaton (CA) and agent-based methods (ABM) simulate spheroid morphology, cell surface receptor density, proliferation, cell cycle, response to chemotactic stimuli and chemotherapeutics (both micro-and nanoscale).
The metastatic route for ovarian cancer, as with other types of cancer, is clearly a multiscale problem, because crucial events in the metastatic outgrowth occur over multiple spatio-temporal scales. These inter-relationships are intrinsically related to multicellular cancer growth and invasion. Multiscale, hybrid models that integrate cellular and tissue scales into a single modelling framework permit simulations that better mimic intracellular signalling pathways, intercellular mechanical interactions and microenvironmental variables to ultimately predict disease progression (Anderson and Quaranta, 2008; Chakrabarti et al., 2012) .
In silico modelling of breast and prostate cancers Mathematical models have been employed for other spheroidforming tumour cells, such as breast and prostate cancer, which are hormone-dependent diseases, as is ovarian cancer. The multiscale modelling of breast cancer initiation, invasion, metastasis, angiogenesis, its microenvironment and advances of experimental approaches have been reviewed elsewhere (Chakrabarti et al., 2012) . Multiscale, agent-based methods (ABM) were combined with signalling pathways to address basic research questions and to identify novel molecular targets (Chakrabarti et al., 2012) . The inclusion of multiple cell types and reaction-diffusion equations reflected the tumourstroma microenvironment. Such an in silico strategy is useful to simulate subcellular ovarian cancer networks, microenvironmental gradients within the peritoneal fluid and the distribution of chemotherapeutics.
Of particular interest is a computed morphometric approach to identify molecular predictors of phenotypes, which uses multidimensional profiling of spheroid morphologies on the basis of 3D culture imaging and genetic analyses of breast cancer cells (Han et al., 2010) . The prediction of spheroid architectures that is based on specific gene expression patterns uses a consensus matrix and hierarchical clustering. The benefit of this method is that consensus clustering, which informs about the stability of identified subpopulations, is combined with a cumulative distribution function to determine the number and shape of these subpopulations (Han et al., 2010) . This in silico strategy is beneficial for molecular subtyping of ovarian cancer spheroids to investigate therapy response factors that are differentially expressed in subpopulations upon anti-cancer treatment.
Computational network modelling has provided a systems view of dysregulated cascades and oncogenic mutations in metastatic breast cancer (Kreeger and Lauffenburger, 2010) . This approach addressed the multivariate nature of the genetic, molecular and cellular network changes that are associated with cancerous diseases. As such, genomic mutations can cause alterations in protein-protein interactions, which lead to altered signalling pathways and cellular behaviour. The advances of this approach are in the integration of predictive methods, such as correlative regression, statistical factor and differential equation analyses, and mutual information-based algorithms, with quantitative experimental data to decipher cancer-related pathways and the efficacy of therapies (Kreeger and Lauffenburger, 2010) . This in silico strategy is useful to simulate networks that are dependent on ovarian cancer-specific mutations.
ABM approaches incorporated patient-specific parameters for cell morphology, density, duct architecture, proliferative and apoptotic indices from pre-surgical patient biopsies (Edgerton et al., 2011; Hyun and Macklin, 2013; Macklin et al., 2012; Macklin et al., 2010) . These simulations use patient-derived tissues, including growth and death indices before and after chemotherapy, and thus can support the decision-making process for individual response rates.
For prostate cancer, two mathematical approaches have been employed; a continuum model to quantitatively describe biomarker dynamics and a Monte Carlo strategy (probabilistic method) to identify hormone-dependent signalling parameters (Swanson et al., 2003; Tasseff et al., 2010) . The continuum model combined the serum prostate-specific antigen level, which is linked to prostate cancer growth, and quantified this level in a simple equation that predicted its production and loss. The prostate-specific antigen was predicted to increase in benign and malignant prostate cells, underlining the biological relevance of this method (Swanson et al., 2003) . Such an in silico strategy can also be used to simulate the dynamics of the serum marker CA-125 (see Box 1).
The authors of the second study investigated androgendependent molecular networks in metastatic prostate cancer, and their mechanistic mathematical model was on the basis of mass action kinetic processes within an ordinary differential Box 3. Ovarian cancer cell polarity Epithelial cells maintain physical contact and polarity with their neighbours through adherens, gap and tight junctions and desmosomes. A loss of cell contacts and polarity is a hallmark of tumorigenesis (Bissell and Radisky, 2001) . Modulation of adherens junctions can promote disease progression upon downregulation of E-cadherin (Cowden Dahl et al., 2008; D'Souza-Schorey, 2005; Martin-Belmonte and Perez-Moreno, 2012) . However, cellular responses are context-dependent; in fact, gain of E-Cadherin expression is an early step in ovarian cancer . Cadherins form complexes with catenins, which support cell polarity and cytoskeletal organisation (Weis and Nelson, 2006; Yamada et al., 2005) , and, upon disruption of the complex, b-catenin translocates into the nucleus. Nuclear b-catenin is linked to high-grade disease (Barbolina et al., 2011) . Connexins, such as Cx43, act as tumour suppressors because the loss of junctional networks enables cancer cells to circumvent growth regulation upon drug treatment (Gershon et al., 2008; Toler et al., 2006) . Claudin-3, claudin-4 and claudin-7 are highly upregulated in ovarian cancer and are associated with increased invasiveness, which is indicative of a metastatic phenotype (Agarwal et al., 2005; Dahiya et al., 2011) . Claudin-3 represents a potential biomarker to complement CA-125 in detection of this disease (Morin, 2007) . Desmosomes have a function in disease progression and Wnt-b-catenin signalling (Chidgey and Dawson, 2007; Green and Gaudry, 2000; Miao et al., 2008) . The atypical proteinase kinase C is linked to defects in cell polarity and decreased progression-free patient survival, which is indicative of an aggressive phenotype (Eder et al., 2005) .
The formation of polarized structures within 3D cultures is linked to cancer cell survival by blocking drug-induced apoptosis (Debnath and Brugge, 2005) . Integrin a6 is highly expressed in ovarian cancer cells, and its inhibition prevents cell growth (Ahmed et al., 2005) . Integrin a6b4 is associated with tumorigenesis because its expression persists in invasive cancer cells, which no longer form stable cell junctions (Alper et al., 2001) . The loss of cell polarity results in an altered spatial distribution of receptor tyrosine kinases, leading to receptor dimerisation and activation by ligands that are normally not available to induce aberrant signalling in polarized cells (Casaletto and McClatchey, 2012) . equation framework, including gene and protein expression levels (Tasseff et al., 2010) . They assume spatial homogeneity, whereas cytosolic and membrane-localised processes are differentiated. Using this approach, several transcription factors and signalling pathways are found to be androgen-independent, thus providing novel treatment options for androgen-insensitive prostate cancers (Tasseff et al., 2010) . This in silico strategy is useful to predict changes in signalling cascades in ovarian cancer cells that are responsive to the anti-cancer treatment employed and microenvironmental parameters (e.g. hydrogel stiffness and co-cultures with stromal cells).
Another biochemically based mathematical model of antiandrogen therapy dissected the heterogeneity of prostate cancer progression, and is suitable as a predictive tool when personalised parameters are incorporated (Jain et al., 2011) . Here, the personalised input parameters address the dynamics of cancer growth and progression, including that of healthy prostate cells, androgen-dependent and castrate-resistant cancer cells. These parameters include the turnover rate of patient-derived cancer cells, testosterone and prostate-specific antigen levels, the frequency of mutation from androgen-dependent to castrationdependent prostate cancer cells and the mutated-cell doubling time. This approach modelled the outcome of either continuous or intermittent treatment and predicted that continuous therapy leads to a disease-free survival of up to five years, whereas an observed increase in androgen-dependent cancer cells suggests that intermittent therapy promotes androgen resistance. As this in silico strategy is based on patient-derived data, it could be used as a personalised prognostic tool (Jain et al., 2011) . These computational modelling approaches for breast and prostate cancer further demonstrate the usefulness of in silico techniques in simulating cancer cell behaviour.
Areas in need of advancement
There is a clear need to improve our current knowledge of the processes underlying the pathogenesis of ovarian cancer to develop more effective, anti-metastatic therapies, thus aligning experimental and simulation approaches. As ovarian cancer is a rather rare malignancy, accounting for 3% of all female cancers in the United States (Siegel et al., 2012) , there are limited opportunities for large clinical trials. Hence, interdisciplinary approaches that combine bioengineered 3D cancer models with computer-based predictions, which integrate multiscale and patient-specific parameters, and with preclinical drug screening tools will be highly beneficial in designing clinical studies.
Multiscale modelling approaches
Experimental testing of computer-generated hypotheses is not trivial, because it requires an open mind from the scientist and the development of new quantitative methods (Anderson and Quaranta, 2008) . There is currently a lack of simulation-based methods to describe the unique metastatic behaviour of ovarian cancer. The molecular processes within multicellular spheroids need to be integrated with those that occur in the host tissue at the genetic, cellular and organelle level (Fig. 2) . Our own mathematical simulations are focused on the design of a multiscale, ovarian cancer model that incorporates the mechanobiological effects of interactions between cancer cells and their microenvironment, and cell-cell adhesions. Such a model uses both hybrid-ABM and multiphase FEA techniques; cellular dynamics and signalling cascades are integrated using a hybrid-ABM approach. To validate our experimental data, we have recently established a spheroid-based ovarian cancer animal model to replicate the peritoneal outgrowth, which reflects the disease progression seen in patients. This intraperitoneal animal model is also suited to screen anti-metastatic therapeutics and, moreover, employs a number of cells (10 5 ) that is physiologically more relevant than the cell number currently used in other animal models (cell numbers 10 6 -10 7 ; Loessner et al., 2013) . However, the learning curve is steep, and extensive investments of time and money are required before a truly integrated, multi-disciplinary approach to in silico, ex vivo and in vivo approaches can be realised. Table 1 outlines the costs for an incremental experiment in a mature laboratory that already works in this interdisciplinary area. In silico modelling requires a mathematician, relatively low costs and time investment, whereas an ex vivo spheroid-based study needs to be conducted by an experienced experimentalist over several weeks and is ten times more expensive than the in silico approach. However, a spheroid-based animal study will last several months, and is both cost and labour-intensive (Loessner et al., 2013) .
Patient-specific calibration of in silico models The use of patient-specific parameters in mathematical models of biological systems is clinically very relevant. To translate multiscale simulations of cancer cell dynamics into clinical assessments, patient-derived data from in situ tissues and databanks (e.g. therapy response and survival time) are integrated into modelling parameters (Graf, 2011 ). These models not only broaden the understanding of cellular processes at the systems level, but might also provide a diagnostic tool for disease progression and a therapeutic tool for improving efficacy of therapy (Konukoglu et al., 2010) . For example, magnetic resonance imaging of brain tumours to analyse the temporal changes in tumour shape have provided continuum simulation parameters to predict the growth characteristics for an individual patient (Konukoglu et al., 2010) . In addition, the inclusion of histopathological data into simulations can estimate the response to therapy (Stamatakos, 2011; Stamatakos et al., 2010 ). An inherent assumption in such patient-specific modelling is that the simulation technique applied (see Box 2) is the most appropriate for the problem being investigated. To address this limitation, simulations need to be verified to ensure their validity within the constraints of the known solution space, and their robustness when tested outside the solution domain.
Conclusions
The development of experimentally verified predictions is one key element for personalised medicine that harbours anatomical, physiological, and molecular factors to give a deeper understanding of the responses of cancerous tissues to mechanobiological stimuli. Given that there are still open questions regarding the biological processes that are associated with metastasis, including how the dissociation of primary tumour cells, the formation of multicellular spheroids, cancer cell invasion at the secondary site and chemoresistance occur, the implementation of computer-based algorithms, which accurately capture all aspects of the metastatic route, is far from being realised. However, the strength in applying a hybrid-ABM, multiphase FEA approach is to improve our current knowledge of ovarian cancer in order to test new hypotheses, or to ascertain signalling avenues that can highlight directions for future experimental and clinical studies. Hence, the road map presented here will be the next step in an important undertaking to determine the unique regulatory signatures of ovarian cancer progression, and uses an in silico model that has been validated with spheroid-based ex vivo and in vivo models. Ultimately, we anticipate that such an approach will allow us to uncover predictive and prognostic biomarkers, and thus lead to new therapeutic interventions.
